Skip to main content
SpringerLink
Log in

Antiphospholipid Syndrome and Cancer

  • Published:
Clinical Reviews in Allergy & Immunology Aims and scope Submit manuscript

Abstract

Thrombosis is a frequent complication of cancer that is a substantial cause of morbidity and mortality. The association of antiphospholipid antibodies (aPL) and cancer has been under investigation for several years. Recent findings suggest an increased prevalence of certain cancers in aPL-positive patients; thus, an intensive search for an occult malignancy is prompted in these patients. In addition, several studies reported on elevated levels of aPL in various malignancies; it seems, however, that aPL levels do not reflect their pathogenicity; therefore, their pathological significance in these subset of patients is still elusive. Continuing research on the association between the antiphospholipid syndrome/aPL and malignancies is important, given the potential impact on the understanding and treatment of both antiphospholipid syndrome and cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lip GY, Chin BS, Blann AD (2002) Cancer and the prothrombotic state. Lancet Oncol 3(1):27–34 (Jan)

    Article  PubMed  CAS  Google Scholar 

  2. Prandoni P, Falanga A, Piccioli A (2005) Cancer and venous thromboembolism. +Lancet Oncol 6(6):401–410 (Jun)

    Article  PubMed  Google Scholar 

  3. De Laat B, Derksen RH, Urbanus RT, de Groot PG (2005) IgG antibodies that recognize epitope Gly40-Arg43 in domain I of β2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 105:1540–1545

    Article  PubMed  CAS  Google Scholar 

  4. Lim W, Crowther MA, Eikelboom JW (2006) Management of antiphospholipid antibody syndrome: a systematic review. JAMA 295(9):1050–1057 (Mar 1)

    Article  PubMed  CAS  Google Scholar 

  5. de Groot PG, Derksen RH (2005) Pathophysiology of the antiphospholipid syndrome. J Thromb Haemost 3(8):1854–1860 (Aug)

    Article  PubMed  Google Scholar 

  6. Kozlowski CL, Johnson MJ, Gorst DW, Willey RF (1987) Lung cancer, immune thrombocytopenia and the lupus inhibitor. Postgrad Med J 63:793–795

    Article  PubMed  CAS  Google Scholar 

  7. Marous RM, Grayzel AL (1979) A lupus antibody syndrome associated with hypernephroma. Arthritis Rheum 22:1396–1398

    Article  Google Scholar 

  8. Langer F, Eifrig B, Marx G, Stork A, Hegewisch-Becker S, Hossfeld DK (2002) Exacerbation of antiphospholipid antibody syndrome after treatment of localized cancer: a report of two cases. Ann Hematol 81(12):727–731 (Dec)

    Article  PubMed  CAS  Google Scholar 

  9. Park CJ, Cho HI, Kim SI (1991) A study on changes of coagulation inhibitors and fibrinolysis inhibitors in patients with liver cirrhosis and hepatoma. J Korean Med Sci 6(1):1–6 (Mar)

    PubMed  CAS  Google Scholar 

  10. Soltesz P, Szekanecz Z, Vegh J, Lakos G, Toth L, Szakall S, Veres K, Szegedi G (2000) Catastrophic antiphospholipid syndrome in cancer. Haematologia (Bp) 30(4):303–311

    Article  CAS  Google Scholar 

  11. Ruffatti A, Aversa S, Del Ross T, Tonetto S, Fiorentino M, Todesco S (1994) Antiphospholipid antibody syndrome associated with ovarian cancer. A new paraneoplastic syndrome? J Rheumatol 21(11):2162–2163 (Nov)

    PubMed  CAS  Google Scholar 

  12. Miesbach W, Scharrer I, Asherson RA (2006) High titres of IgM-antiphospholipid antibodies are unrelated to pathogenicity in patients with non-Hodgkin’s lymphoma. Clin Rheumatol 24 (May)

  13. Donner M, Bekassy NA, Garwicz S, Holmberg L, Wiebe T (1992) Cerebral infarction in a girl who developed anticardiolipin syndrome after acute lymphoblastic leukemia. Pediatr Hematol Oncol 9(4):377–379 (Oct–Dec)

    PubMed  CAS  Google Scholar 

  14. Mouas H, Lortholary O, Eclache V, Leroux G, Casassus P, Guillevin L, Raphael M (1994) Antiphospholipid syndrome during acute monocytic leukaemia. Eur J Haematol 53(1):59–60 (Jul)

    Article  PubMed  CAS  Google Scholar 

  15. Lossos IS, Bogomolski-Yahalom V, Matzner Y (1998) Anticardiolipin antibodies in acute myeloid leukemia: prevalence and clinical significance. Am J Hematol 57(2):139–143 (Feb)

    Article  PubMed  CAS  Google Scholar 

  16. Yahata N, Ohyashiki K, Iwama H, Katagiri T, Kodama S, Tauchi T, Yaguchi M, Toyama K (1997) Chronic myelomonocytic leukemia in a patient with antiphospholipid syndrome: first case report. Leuk Res 21(9):889–890 (Sep)

    Article  PubMed  CAS  Google Scholar 

  17. Duncombe AS, Dalton RG, Savidge GF (1987) Lupus-type coagulation inhibitor in hairy cell leukaemia and resolution with splenectomy. Br J Haematol 65(1):120–121 (Jan)

    PubMed  CAS  Google Scholar 

  18. Asherson RA (2000) Antiphospholipid antibodies, malignancies and paraproteinemias. J Autoimmun 15(2):117–122 (Sep)

    Article  PubMed  CAS  Google Scholar 

  19. Asherson RA, Garcia-Carrasco M, Zeron PB, Ramos-Casals M. (2002) Antiphospholipid antibodies and malignancies. In: Asherson RA, Cervera J, Piette C, Shoenfeld Y (eds) The antiphospholipid syndrome II: autoimmune thrombosis. Elsevier, pp 317–327

  20. Gomez-Puerta JA, Cervera R, Espinosa G, Aguilo S, Bucciarelli S, Ramos-Casals M, Ingelmo M, Asherson RA, Font J (2006) Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients. Semin Arthritis Rheum 35(5):322–332

    Google Scholar 

  21. Jude B, Goudemand J, Dolle I, Caron C, Watel A, Tiry C, Cosson A (1988) Lupus anticoagulant: a clinical and laboratory study of 100 cases. Clin Lab Haematol 10(1):41–51

    PubMed  CAS  Google Scholar 

  22. Schved JF, Dupuy-Fons C, Biron C, Quere I, Janbon C (1994) A prospective epidemiological study on the occurrence of antiphospholipid antibody: the Montpellier Antiphospholipid (MAP) Study. Haemostasis 24(3):175–182 (May–Jun)

    PubMed  CAS  Google Scholar 

  23. Finazzi G (1997) The Italian registry of antiphospholipid antibodies. Haematologica 82(1):101–105 (Jan–Feb)

    PubMed  CAS  Google Scholar 

  24. Zuckerman E, Toubi E, Golan TD, Rosenvald-Zuckerman T, Sabo E, Shmuel Z, Yeshurun D (1995) Increased thromboembolic incidence in anti-cardiolipin-positive patients with malignancy. Br J Cancer 72(2):447–451 (Aug)

    PubMed  CAS  Google Scholar 

  25. Stasi R, Stipa E, Masi M, Oliva F, Sciarra A, Perrotti A, Zaccari G, Papa G (1993) Antiphospholipid antibodies: prevalence, clinical significance and correlation to cytokine levels in acute myeloid leukemia and non-Hodgkin’s lymphoma. Thromb Haemost 70(4):568–572 (Oct 18)

    PubMed  CAS  Google Scholar 

  26. Pusterla S, Previtali S, Marziali S, Cortelazzo S, Rossi A, Barbui T, Galli M (2004) Antiphospholipid antibodies in lymphoma: prevalence and clinical significance. Hematol J 5(4):341–346

    Article  PubMed  CAS  Google Scholar 

  27. Miesbach W, Scharrer I, Asherson R (2006) Thrombotic manifestations of the antiphospholipid syndrome in patients with malignancies. Clin Rheumatol 25:1–5 (Jan)

    Article  Google Scholar 

  28. Yoon KH, Wong A, Shakespeare T, Sivalingam P (2003) High prevalence of antiphospholipid antibodies in Asian cancer patients with thrombosis. Lupus 12(2):112–116

    Article  PubMed  CAS  Google Scholar 

  29. Miesbach W, Asherson RA, Cervera R, Shoenfeld Y, Gomez Puerta J, Bucciarelli S, Espinoza G, Font J and the members of the CAPS Registry Group (2006) The catastrophic antiphospholipid (Asherson’s) syndrome and malignancies. Autoimmun Rev 6(2):94–97

    Article  PubMed  CAS  Google Scholar 

  30. Endler G, Marsik C, Jilma B, Schickbauer T, Vormittag R, Wagner O, Mannhalter C, Rumpold H, Pabinger I (2006) Anti-cardiolipin antibodies and overall survival in a large cohort: preliminary report. Clin Chem 52(6):1040–1044 (Jun)

    Article  PubMed  CAS  Google Scholar 

  31. Cocca BA, Seal SN, D’Agnillo P, Mueller YM, Katsikis PD, Rauch J, Weigert M, Radic MZ (2001) Structural basis for autoantibody recognition of phosphatidylserine-beta 2 glycoprotein I and apoptotic cells. Proc Natl Acad Sci USA 98(24):13826–13831 (Nov 20)

    Article  PubMed  CAS  Google Scholar 

  32. Buschmann C, Fischer C, Ochsenhirt V, Neukirch C, Lackner KJ, von Landenberg P (2005) Generation and characterization of three monoclonal IgM antiphospholipid antibodies recognizing different phospholipid antigens. Ann N Y Acad Sci 1051:240–254 (Jun)

    Article  PubMed  CAS  Google Scholar 

  33. Langer F, Amirkhosravi A, Loges S, Meyer T, Eifrig B, Hossfeld DK, Fiedler W, Francis JL (2004) An in vitro study on the mechanisms of coagulation activation in acute myelogenous leukemia (AML): role of tissue factor regulation by cytotoxic drugs and GM-CSF. Thromb Haemost 92(5):1136–1146 (Nov)

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine B and Center for Autoimmune Diseases, Chaim Sheba Medical Center, Tel-Hashomer, 52621, Israel

    Eyal Reinstein & Yehuda Shoenfeld

  2. Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel

    Eyal Reinstein & Yehuda Shoenfeld

Authors
  1. Eyal Reinstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yehuda Shoenfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Eyal Reinstein or Yehuda Shoenfeld.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reinstein, E., Shoenfeld, Y. Antiphospholipid Syndrome and Cancer. Clinic Rev Allerg Immunol 32, 184–187 (2007). https://doi.org/10.1007/s12016-007-0003-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12016-007-0003-1

Keywords

Search

Navigation